Sight Sciences, Inc. has announced the launch of its next-generation OMNI® Surgical System for microinvasive glaucoma surgery (MIGS) procedures. The OMNI Surgical System combines two distinct angle procedures – ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS device that allows surgeons to target all three points of aqueous humor outflow resistance – trabecular meshwork, Schlemm’s canal and distal collector channels.
“We designed the next generation of our OMNI Surgical System to provide improved ergonomics, intuitive use and smooth microcatheter deployment and retraction, while continuing to deliver excellent outcomes as a standalone treatment, or as a procedure performed in conjunction with cataract surgery,” said Sight Sciences Chief Commercial Officer, Shawn O’Neil. “We’re excited to announce the availability of this improved system, which incorporates many changes based on feedback from our physician customers.”
The OMNI Surgical System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example Healon®, HealonGV®, Amvisc®, or PROVISC®, during ophthalmic surgery. It is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures.
The upgraded system features several updates designed to enhance its ergonomics and usability. An updated Luer lock fitting and pull pin to provides increased efficiency in the priming and preparation of the device. An ergonomic handle and flexi-grip surface adds a comfortable fit and provides stability in the surgeon’s hand. Enhanced gearing and an intuitive wheel design enables seamless deployment and retraction of the microcatheter.
Initial published results from early use of the OMNI Surgical System show meaningful reductions in intraocular pressure (IOP) and medication use. Several large-scale, multi-center retrospective and prospective MIGS clinical studies further evaluating the OMNI Surgical System are underway and in their advanced stages.
The OMNI Surgical System is a tool, not a treatment, and is indicated for use as specified above; it is not specifically cleared by the FDA to lower intraocular pressure in patients with open angle glaucoma.
Full news release: https://www.sightsciences.com/us/sight-sciences-introduces-the-next-generation-omni-surgical-system-for-microinvasive-glaucoma-surgery-3/